Clinical Trial Update: A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating INCA033989 as a monotherapy or in combination with ruxolitinib in participants with myeloprolife…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• INCA033989
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myeloproliferative Neoplasms | Phase 1 | Status: RECRUITING